Featured
Rimsys Announces Rimsys AI to Eliminate Repetitive Tasks and Enhance Decision-Making for MedTech Regulatory Teams
Rimsys, the leading Regulatory Information Management (RIM) platform for the MedTech industry, today announced the launch of Rimsys AI, a suite of embedded artificial intelligence (AI) agents.
Regulatory Strategy as a Competitive Advantage
This article is an excerpt from the Regulatory strategy as a competitive advantage ebook.
Table of Contents
- The regulatory revenue opportunity
- Regulatory responsibilities
- Limitations of the "cost-center" approach to regulatory affairs
- Regulatory as a revenue function
- Competitive advantage #1: Faster time to market
- Competitive advantage #2: Cost avoidance
- Competitive advantage #3: Out-pacing competitors
- Why invest in regulatory/revenue alignment?
- Getting started - 3 steps to move towards a revenue-aligned RA team
It is well known that medical technology (medtech) companies are highly regulated, given the potential risks their products present. Understanding and complying with the complex regulations in each country is, therefore, a necessary part of marketing and selling medical devices. To realize any revenue from a medical device, it must not only demonstrate compliance with all applicable regulations, it must also receive and maintain market clearance from each country in which it is to be sold. No market clearance means no revenue. Given the key role regulatory compliance plays in revenue attainment, regulatory teams, tools, and processes present a significant opportunity for differentiation for organizations willing to invest in them.
For the majority of medtech companies, however, regulatory departments have traditionally been treated as operational cost centers, with departmental improvements focused on cost reduction and efficiency improvements. Limited investment in people and tools, and limited interest in digital transformation, have left regulatory teams across the medtech industry underfunded and under-resourced.
This has led to great resourcefulness within the RA community, where most members can point to heroes within their team who worked long hours to meet a submission deadline, headed off a disaster by uncovering a pending expiration, created ad-hoc systems to organize information and streamline communication between the RA and QA teams for smoother audits, or have otherwise gone above and beyond their typical responsibilities.
Regulatory teams, however, have the potential to be a revenue-driving competitive weapon for companies that are willing to look at them a little differently and invest in regulatory performance above regulatory cost-effectiveness. Well-supported regulatory teams can provide a true competitive advantage by providing the resources and direction to:
- Capture market share by being first to market with novel devices.
- Avoid lost revenue by effectively tracking and planning for registration renewals/updates.
- Out-pace competitors and grow market share by adapting to regulatory changes more quickly and taking advantage of competitors’ non-compliance or inability to enter a new market.
We believe we are entering a new era for regulatory affairs within the medtech industry. One in which RA teams have a seat at the table when go-to-market, competitive positioning, and strategic decisions are being made.
In the medtech industry, regulatory affairs (RA) teams have a broad range of responsibilities across the product lifecycle:
Premarket regulatory strategy
Obtaining market clearance for a new medical device is the primary activity typically attributed to RA teams. It is not unusual for a regulatory team to be given market entrance projects with little warning, but ideally, the RA team would be brought in as early as possible to contribute to go-to-market discussions.
Premarket regulatory strategy, at a minimum, involves:
- Determining the most appropriate pathway to market approval. For example, a 510(k) or PMA submission in the U.S.
- Working with quality, product, and other teams to gather information needed for market submission.
- Establishing communication with applicable regulatory bodies and third-party approved auditors.
- Compiling and submitting required documentation for market approval. This includes managing follow-up activities, questions, and requests for additional information throughout the approval process.
Forward-thinking organizations often look to bring in RA teams even earlier in the process. As regulatory experts, RA professionals can provide unique insight into product development plans. In consultation with R&D teams, can help to refine product strategies, and steer development in areas that will reduce regulatory hurdles when new products are ready to be commercialized.
Maintaining regulatory compliance for existing products
While the primary focus of regulatory teams is often considered to be new market submissions, the majority of their time is actually spent on maintaining compliance for products that are already in-market. Even in situations where market registrations do not expire, constant vigilance is required to ensure that devices remain compliant with current regulations. These efforts take a considerable time for a typical RA team because information is often spread across disparate systems, where it can be difficult to find and confirm.
Maintaining regulatory compliance for approved devices includes:
- Staying on top of changing standards and making changes as required to existing technical files and other documentation.
- Submitting appropriate documentation updates when there is a change made that could potentially affect the efficacy or safety of the product, such as a material switch or facility change.
- Understanding pending regulatory changes and proactively addressing any that have an impact on devices currently in-market.
- Tracking registration expirations and preparing for timely re-submissions to ensure there is no lapse in market clearance.
Post-market activity
Post-market surveillance and vigilance activities are required by most countries and should involve the cooperation of the quality and regulatory teams. Ensuring that changing post-market reporting requirements are understood and complied with is an important regulatory responsibility.
Regulatory teams typically play a role in:
- Post-market surveillance of adverse events, complaints, and any issues associated with a device in the field.
- Assembling and submitting any required periodic safety reports to country/regional health authorities.
- Post-market vigilance and reporting of serious events to the appropriate regulatory agencies.
- Any required communication with regulatory authorities regarding adverse events or concerning trends in product quality.
Ask any RA professional, and they are likely to tell you that they work long hours and are often scrambling to meet looming deadlines...
To continue reading this ebook, download the full version.
.jpeg)
2023 Regulatory performance report
Today at Rimsys, we unveiled the 2023 MedTech Regulatory Performance Report, a new set of insights into the state of medtech regulatory affairs. Compiled based on interviews with 200 regulatory professionals and executives, the study provides a detailed look into how regulatory teams are staffed, their processes, the tools they use, and ultimately how they perform.
Why did we create this study? There were two driving factors behind the research. The first was a common theme that we heard from a number of our customers: Regulatory leaders don’t have clear data and benchmarks. They don’t necessarily know how long a new market submission should take, and how to plan for or assess the work of their teams. While other studies look at the medtech industry broadly or the state of the regulatory profession, this study tries to build a comprehensive resource for regulatory (and company) leaders.
The second factor was really for ourselves and the team at Rimsys. As a company building solutions specifically for medtech regulatory affairs, we wanted more insight into where companies were successful, where they struggled, and where we can add value.
What did we find? Regulatory teams perform a lot of hero work and rate themselves highly for their accomplishments. At the same time there is a lot of opportunity for process improvements, and companies that invest in digital transformation for regulatory affairs see better performance.
Regulatory professionals are superheroes
Regulatory teams are generally pretty small. Most companies have less than 10 full-time regulatory professionals. These small teams complete an enormous amount of work. Last year on average, RA teams completed 50 license renewals, 50 license updates, and 10 new market submissions. This is impressive output.
Digging a bit under the covers, we found that this output relied heavily on the support of external consultants. 90% of companies use consultants to keep pace with their regulatory workload. Front-line employees also struggle with burnout. They were much more likely to report feeling under-resourced than regulatory leaders.
But process problems persist
A lot of regulatory work remains extremely manual. 70% of regulatory teams spend half their time or more on repetitive administrative tasks. All of this manual work increases the frequency of errors and required rework. 61% of companies reported a major non-compliance incident in the past 2 years.
Manual work also makes it difficult to complete regulatory projects in a timely fashion. Teams completed a lot of projects, but each took a long time. Over half of all companies spend 4 months or more on license renewals, license updates, and new market submissions.
Moving regulatory affairs forward
As regulatory requirements become more complex, there’s a natural question about how teams will work moving forward. MDR & IVDR in Europe have significantly increased the regulatory workload required to bring and keep products on the market. Will organizations be able to keep pace with the same resources, tools, and processes?
No, and the performance report shows that medtech companies are investing to improve their regulatory capabilities. The majority of companies are planning to increase the sizes of their RA teams in 2023, and 40% expect to increase their investments in regulatory software. Companies are increasingly adopting specialized software to better support regulatory processes.
Dig into the survey results
The full survey results provide insights into more aspects of regulatory performance. They show that companies need to take a deeper look into their processes and how regulatory resources are allocated. There are two ways to learn more:
- Visit the survey page to see the full results (the survey whitepaper can be downloaded at no cost)
- Watch the recording of our webinar with PA Consulting. We discuss the survey results in more detail and share our regulatory predictions for 2023
The Real Cost of “We’ll Build It Ourselves”
If you are reading this from inside a large MedTech organization, you may be thinking: we have ten times the engineering staff. Why can’t we just build this ourselves?
We-Should-Just-Build-This-Ourse…
It is a fair question.
But software has a well-known paradox. Adding more people to a complex project does not make it go faster. It usually makes it go slower. More coordination. More handoffs. More meetings about meetings. More surface area for misalignment
A large IT organization is optimized for breadth — supporting dozens of systems, managing infrastructure, keeping the lights on across the enterprise
That is valuable work.
But it is fundamentally different from building and sustaining a deep vertical product over a decade.
The people on your team have day jobs. They run devices through regulatory pathways, manage quality systems, support manufacturing, and commercialize products globally
Building a regulated platform is not a side quest.
It is a second company
What the Numbers Actually Look Like
When people compare license fees to internal builds, they stop at the wrong baseline
The real comparison is:
Licensing a specialized platform
versus
Standing up and operating a regulated software company inside your enterprise
Product management.
UX research.
Engineering.
Regulatory SMEs.
Validation and QA.
Security operations.
Compliance programs.
24/7 support.
Infrastructure.
Multi-year modernization
AI makes some of that faster.
It does not make any of it optional
With a specialized vendor, that investment is amortized across an entire customer base.
With an internal build, the full long tail of ownership falls on you
And most of that spend ends up recreating the 80 percent that has already been solved — all because someone decided the remaining 20 percent justified building from scratch
The return on that 20 percent rarely survives honest scrutiny.
The Questions That Should Keep You Honest
It is easy to get excited about how fast something can be built.
The harder exercise is asking what happens in year three, year five, year eight
When your VP of Regulatory Affairs leaves, who maintains validation documentation?
When regulations change across jurisdictions simultaneously, who redesigns workflows and pushes a validated release before the deadline?
When an auditor asks for change control history and disaster recovery test results, who is accountable?
Internal initiatives often stumble not because engineers cannot prototype, but because sustaining them for a decade is brutally hard
Sponsors move on. Budgets change. Teams reorganize.
Regulatory systems do not get to pause.
They must remain inspection-ready through acquisitions, divestitures, and leadership turnover
Systems of record are commitments, not experiments
AI Changed the Tools, Not the Gravity
I am genuinely excited about what AI enables. It will reshape regulatory operations, reduce headcount growth, compress timelines, and raise expectations for every vendor in this space
What it has not done is repeal gravity.
Most of what AI replaces today is busy work. That is enormously valuable. But busy work was never the strategic bottleneck
The hard parts remain.
- Deciding submission strategy.
- Interpreting regulator feedback.
- Designing defensible workflows.
- Staying inspection-ready.
- Running global rollouts
Agents help teams move faster.
They do not decide what is safe, defensible, or durable
In MedTech, software is not just built.
It is designed, governed, operated, and defended
And gravity still applies.
Day Zero Is Easy. Day One Is Where It Gets Hard
There is something I keep coming back to in these conversations.
You can go from idea to prototype incredibly fast right now. That is the day-zero problem, and AI has essentially solved it. You can spit out working code, scaffold an integration, and stand up a proof of concept in a week
But the nuance around an actual business workflow — the day one and beyond activities — those are dramatically harder than day zero ever was
Software engineering done well is craftsmanship.
There is more to it than generating code and turning a prototype into something a regulated enterprise can depend on. It means thinking about edge cases, failure modes, upgrade paths, observability, and long-term operability. It means deleting as much as adding. Simplifying interfaces. Collapsing concepts down to what actually matters
Inside my own teams, I see impressive first versions all the time.
That is not the hard part anymore.
The hard part is everything that comes after
We-Should-Just-Build-This-Ourse…
Faster Engineering Just Pushes Work Somewhere Else
There is a tradeoff that rarely makes it into the first ROI spreadsheet.
AI compresses build cycles. In regulated companies, that speed shows up downstream. More releases mean more validation, more SOP updates, more training, more compliance review, and more audit prep
Engineering gets cheaper.
Governance becomes the constraint
There is also a subtler version of this problem.
Agents make it easy to generate output at scale. More workflows. More automation. More code.
But in regulated environments, every new service or automation path increases surface area. More things to secure. More things to validate. More things to explain to auditors
Speed without discipline creates complexity faster.
For CTOs, that is an architectural concern.
For Regulatory leaders, that is an inspection risk.
Are You Trying to Be a Software Company?
This is the part of these conversations that most often gets skipped.
A MedTech company is not a software shop. Most are largely outsourced IT organizations, and there is nothing wrong with that. The core business is devices, science, R&D, manufacturing quality, clinical programs, and global commercialization
When internal teams talk about building major regulatory platforms, the question is not whether they can spin up a prototype.
It is whether they want to operate a full-time software company inside their enterprise
Building software at scale is a people problem. It is not a technology problem. The constraint is coordination, judgment, institutional knowledge, and sustained focus over years
The people problem does not get fixed by agents and AI.
Regulatory platforms are deeply vertical. They encode jurisdiction-specific rules, regulator expectations, submission templates, QMS integrations, inspection trails, and post-market obligations
That knowledge is earned slowly.
It lives in product decisions, data models, operating procedures, and support playbooks.
AI will reshape how these platforms evolve.
It does not remove the learning curve that created them
AI Agents and the Confidence Shift Inside MedTech IT
In some MedTech IT planning meetings, a new kind of confidence has started to show up.
Not everywhere. Not in every organization. But often enough that it is worth paying attention to.
It is subtle. Casual. The kind that appears when something new begins to feel inevitable
A VP of IT or a CIO sits in a planning meeting. Someone pulls up a demo. An AI agent drafts a regulatory summary, generates a workflow, and scaffolds an integration. It looks impressive. It is impressive
Then someone says it:
Why are we paying for a platform when we could build this ourselves?
I understand the impulse.
SaaS valuations are volatile. Boards are pressing on efficiency. Hiring is under scrutiny everywhere. AI arrives, and suddenly there is a clean story. Automate friction. Avoid headcount growth. Modernize everything
Some of that is real.
I am optimistic about AI. In the right hands, it is a genuine superpower
But hope, cost pressure, aggressive marketing, and very human psychology are colliding right now. That collision is shaping how executives talk about technology strategy
In regulated industries, that matters.
The Confirmation Bias Problem
When leaders already feel pressure to reduce costs or flatten organizations, they naturally gravitate toward stories that validate those instincts. Flashy demos and headlines about agents replacing departments reinforce the belief that a breakthrough must be right around the corner
Once that belief sets in, messy operational details get discounted. Risk gets deferred.
That does not make the technology fake.
It does explain why ambition so often outruns delivery reality
For CTOs and Regulatory leaders, this is the moment to slow the conversation down.
Because prototypes are not platforms.
What AI Actually Changes
Years ago, Harvard Business Review wrote about the “hidden data factory,” the idea that organizations accumulate thousands of small one-off efforts to clean data, reconcile systems, patch workflows, and keep operations moving. No single fix ever justifies a major initiative. In aggregate, it quietly costs millions
That concept maps directly to what AI is good at today.
Inside engineering organizations, we call this work toil.
The repetitive, manual, low-judgment effort that keeps systems running but should not consume the time of highly trained people. Environment setup. Data reconciliation. Migration scripts. Test generation. Documentation drafts. Classification lookups. Compliance artifacts
AI is excellent at eliminating toil. It removes friction, collapses queues, and gives teams back time
In regulated environments, that is meaningful.
But here is the distinction that matters:
Eliminating toil does not eliminate accountability
It does not remove the need for architecture, UX design, validation strategy, regulatory interpretation, or operational ownership.
What it does is allow smaller, more senior teams to focus on the work that actually differentiates platforms.
That is very different than from saying agents replace the platforms themselves
Why MedTech Regulatory Teams Are Delegating EUDAMED to IT
And Why That Creates Bigger Problems Over Time
As EUDAMED implementation accelerates and the UDI/Devices module becomes mandatory in May of 2026, many MedTech companies have made a seemingly practical decision. They hand EUDAMED compliance to IT.
At first glance, the logic feels sound. EUDAMED is a system. It requires integrations, data transmission, and technical connectivity. IT already owns those capabilities, so the project lands there.
But this handoff reveals a deeper misunderstanding of what EUDAMED actually represents. It is a tool that enables manufacturers to meet ongoing regulatory obligations that touch product data, submissions, post-market activities, and lifecycle management. EUDAMED also enables manufacturers’ ACTOR partners like Notified Bodies, Authorized Representatives, Importers, and Distributors to meet their obligations under those EU regulations. Treating it as an isolated, one-time IT project creates risks to EU regulatory compliance that grow and spread across partners over time. MDR/IVDR regulatory compliance cannot be established and maintained with a one-time technical integration.
The first problem with delegating EUDAMED to IT is what it signals internally. It frames the regulation as a single event rather than a continuous program.
EUDAMED is not just about getting data into a database. It requires ongoing updates tied to regulatory changes, product modifications, vigilance activities, certificates, and market status. Every change across the product lifecycle can trigger downstream updates in EUDAMED.
When EUDAMED is positioned as a one-time event, organizations underestimate the scope, effort, and ownership required to maintain compliance over time. That gap does not show up immediately. It appears months later when updates are missed; data falls out of sync, or responsibilities become unclear.
IT teams often take on EUDAMED with the expectation that once the pipes are built, the work is largely done. In reality, the opposite happens.
As regulatory data changes, IT becomes the default escalation point for updates they do not own and cannot validate. They are asked to manage regulatory timelines, interpret data requirements, and support continuous updates that fall outside their core mandate.
This creates friction on both sides. Regulatory teams feel blocked by technical dependencies. IT teams feel burdened by compliance work they were never meant to manage. Over time, updates slow down, workarounds emerge, and risk quietly increases.
The most damaging consequence of delegating EUDAMED to IT is architectural. When EUDAMED operates outside of a centralized Regulatory Information Management system, organizations lose the opportunity to reuse data and reduce burden across the business.
Most of the data required for EUDAMED already exists within product information management and resource planning systems. Product registrations, certificates, submissions, UDI, and post-market data are not new. They are part of the regulatory lifecycle. When EUDAMED is disconnected from RIM, teams are forced to duplicate work, reconcile inconsistencies, and manually manage updates across systems.
Instead of becoming a natural extension of regulatory operations, EUDAMED turns into another silo. One that increases workload rather than streamlining it.
Establishing and maintaining regulatory information in EUDAMED is a regulatory obligation, not a technical one. While IT plays a critical role in enablement and integration, there should be a strong partnership between regulatory and IT (or a third-party submitter), but IT shouldn’t own it completely.
When EUDAMED is managed as part of a centralized RIM approach, organizations gain consistency, traceability, and reuse. Regulatory teams can leverage existing data, control updates at the source, and reduce the ripple effects of change across departments. IT supports the infrastructure, but regulatory owns the process.
This shift also changes how organizations think about compliance. Instead of reacting to EUDAMED as a standalone requirement, they treat it as part of a broader regulatory operating model that supports long-term compliance and growth.
Delegating EUDAMED to IT is rarely a conscious strategy. It is usually a symptom of fragmented regulatory operations and unclear ownership.
As MedTech companies scale globally and regulatory expectations continue to evolve, these handoffs become harder to sustain. EUDAMED exposes the cost of treating regulatory compliance as a series of isolated projects rather than an ongoing operational discipline.
The companies that navigate EUDAMED successfully are not the ones with the most complex integrations. They are the ones that anchor EUDAMED within regulatory operations, supported by centralized RIM systems that establish data consistency and reduce duplication, improve visibility, and spread the burden across the organization in a controlled way.
Agentic AI and the Future of Regulatory Operations
Why Regulatory Operations Is Ready for Agentic AI
Regulatory operations teams are under increasing pressure. Global regulatory complexity is rising, data volumes continue to grow, and teams are expected to move faster, often without additional headcount. At the same time, employee turnover and fragmented systems make it harder to maintain continuity and institutional knowledge.
As outlined in the RIM & AI Maturity in MedTech Executive Guide, many organizations are still operating with scattered regulatory data, reactive processes, and manual workflows. These conditions increase compliance risk and slow growth.
This environment has created the conditions where a more advanced form of AI can deliver meaningful value. That is where agentic AI comes into play, not as a replacement for regulatory expertise, but as a way to strengthen how regulatory operations function day to day.
What Is Agentic AI and Why It Matters
Most AI used in regulatory environments today is assistive. It helps classify documents, extract text, or answer questions when prompted. Agentic AI goes further by operating within defined workflows and processes.
Agentic AI systems can monitor structured regulatory data continuously, identify upcoming risks or deadlines, recommend actions based on rules and historical context, and surface next steps within governed processes. Instead of responding to requests, agentic AI supports execution by working alongside regulatory teams inside their operational systems.
The distinction is important. In regulated environments, value does not come from generative output alone. It comes from intelligence that is embedded, auditable, and aligned with how regulatory work actually gets done.
Moving Regulatory Teams Off the Data Treadmill
The executive guide describes early-stage regulatory teams as being stuck on a back-office data treadmill. Highly skilled professionals spend a disproportionate amount of time searching for information, reconciling spreadsheets, and repeating manual tasks rather than applying their expertise strategically.
Agentic AI helps reduce this burden by continuously organizing and validating regulatory data, identifying missing metadata or inconsistencies early, and reducing reliance on individual memory or tribal knowledge. Over time, this improves not just efficiency, but operational resilience. Teams become less vulnerable to audits, turnover, and last-minute regulatory surprises.
Why Agentic AI Depends on Operational Maturity
One of the most important insights from the paper is that AI value scales with RIM maturity. Advanced AI capabilities are not effective without centralized regulatory information and standardized processes .
At higher maturity levels, AI can surface upcoming risks across markets and renewals, analyze submission history to recommend reusable content, and identify bottlenecks before they impact timelines. At this stage, agentic AI begins to function as an operational partner, helping teams anticipate issues rather than react to them.
This is also where many organizations encounter friction. Skipping foundational steps may create the appearance of progress, but it limits reliability and long-term impact. Agentic AI is only as effective as the data, governance, and workflows it operates within.
From Task Automation to Predictive Compliance
At the most mature stage of regulatory operations, AI becomes fully embedded in daily work. The guide describes this level as one where real-time monitoring, predictive analytics, and continuous improvement are standard practice .
In this environment, agentic AI supports predictive compliance by identifying emerging risks, highlighting resource constraints, and improving visibility across submissions and renewals. These insights allow teams to act earlier and with greater confidence.
The paper is clear on one point. AI enhances regulatory expertise, but it does not replace it. Human judgment remains essential for interpretation, decision-making, and accountability. The real value of agentic AI is that it frees regulatory professionals from low-value work so they can focus on the decisions that matter most .
Regulatory Operations as the Heart of Compliant Growth
The most significant impact of agentic AI is not automation alone. It is the elevation of regulatory operations from a reactive support function to the heart of compliant growth.
Organizations that invest in strong RIM foundations, data governance, and workflow integration are better positioned to apply AI in a way that is safe, scalable, and durable. When implemented thoughtfully, agentic AI helps regulatory operations keep pace with growth, reduce risk, and support faster, more confident decision-making across the business.
The Future of MedTech Compliance: How AI Is Transforming Regulatory Affairs
MedTech regulatory affairs teams are facing a turning point. Regulations are expanding in number and complexity, resources are limited, and manual processes cannot keep up. At the same time, artificial intelligence (AI) has become a serious topic of discussion in regulatory circles. Leaders are beginning to ask: How can AI help us manage change, reduce risk, and accelerate compliance efforts?
The answer is clear: AI is no longer just a buzzword. When combined with effective regulatory information management (RIM), it can be a powerful enabler of efficiency, accuracy, and strategic decision-making.
Why AI is Trending in Regulatory Affairs
The Surge of Regulatory Data
Regulatory teams must now track requirements from multiple global markets. Each regulator frequently updates its regulations, guidances, templates, and recognized standards, which creates large volumes of data to organize and analyze. AI can scan and classify this information, highlight changes, and prepare it for structured use within RIM systems.
Doing More with Limited Resources
Most teams are expected to deliver more without additional staff. High turnover makes continuity difficult, and according to the 2024 RAPS Global Workforce Report, the number of professionals “open to work” has grown in North America and Europe. AI offers relief by taking on repetitive tasks such as document formatting or data entry, allowing experts to focus on higher-value work.
Global Complexity and Diverging Standards
No two markets are exactly alike. AI can help by flagging differences, surfacing potential risks, and recommending reusable content drawn from a company’s submission history. Faster, more accurate submissions directly improve time-to-market and compliance outcomes.
The RIM & AI Adoption Maturity Model
Not every organization is ready to fully embrace AI. Success depends on RIM maturity: how structured and centralized your regulatory processes and data are. The RIM & AI Adoption Maturity Model provides a roadmap from basic to optimized states.
- Levels 0–2: Early Stage
- Data is siloed and processes are ad hoc. AI provides value in isolated ways, such as cleansing records or scanning for regulatory changes.
- Level 3: Proactive
- A RIM system centralizes information. AI begins to surface reminders, deadlines, and global impact assessments.
- Level 4: Well Managed
- Processes are standardized across the lifecycle. AI generates insights, monitors KPIs, and supports reuse of regulatory content.
- Level 5: Optimized
- AI is fully embedded, delivering predictive analytics, continuous monitoring, and smarter decision-making.
Practical Applications of AI Today
Today, regulatory teams see the greatest opportunities in:
- Regulatory submissions: Automatically detecting changes in templates and suggesting updates.
- Document classification: Using natural language processing to tag and organize regulatory documents.
- Regulatory intelligence: Monitoring health authority updates and highlighting what matters most.
- Impact assessments: Linking changes (e.g., regulations/standards/design) directly to the affected products and registrations and evaluate the potential impact.
- Content reuse: Recommending approved content to accelerate submissions.
How to Start Your AI Journey in Regulatory Affairs
Adopting AI is not about jumping to the most advanced capabilities overnight. Instead, consider these steps:
- Assess your RIM maturity. Where does your organization sit on the 0–5 scale? What foundational gaps (data centralization, process standardization) need to be addressed first?
- Identify quick wins. Focus on repetitive, rules-based tasks where AI can add value without major disruption.
- Implement governance. Establish policies for safe, compliant AI use, particularly around data privacy and model training.
- Pilot in phases. Start small, validate results, and expand AI use as confidence and maturity grow.
- Keep people at the center. AI should enhance the expertise of regulatory professionals, not replace it.
Building a Smarter Future for MedTech Compliance
AI is becoming a trending topic in regulatory affairs not just because it’s new, but because it directly addresses the challenges teams face: rising complexity, limited resources, and scattered data.
For organizations that take this approach, the benefits are clear: lower compliance risk, faster execution, and stronger competitive positioning. AI does not replace regulatory professionals. Instead, it enables them to spend less time on manual tasks and more time on strategic contributions that improve patient access to life-changing technologies.
In other words, AI isn’t about futuristic transformation. It’s about helping regulatory teams step off the “data treadmill” and reclaim their time for what matters most: bringing safe, life-changing medical technologies to patients faster.
